Core evidence clinical impact summary for romidepsin in CTCL

Outcome measure	Evidence	Implications
Disease-oriented evidence
Response rate	Substantial	Patients with refractory CTCL have partial and complete response to drug.
Improvement in quality of life	Moderate	Patients had a meaningful reduction in pruritus.
Patient-oriented evidence
Safety and tolerability	Moderate	Grade 3 and 4 toxicities were observed but infrequently led to dose limitations.
Economic evidence
Health care resource utilization	Limited	Direct cost of the drug at the approved dosing level is currently higher than other novel agents used in CTCL.
Cost-effectiveness	No evidence